Our Journey
_
2009 – 2010
_
- Company incorporated
- Started as a virtual company with a focus on sales distribution of sustainable portfolio of generics in US markets
2011 – 2013
_
- Developed multiple sales channels through GPOs, wholesalers & pharmacies
- Acquired wholesaler licenses in all 50 states
- Ventured into OSD ANDA development through partnerships
2014 – 2016
_
- Partnerships with CROs and CDMOs globally for development/ Co- development of ANDAs and in licensing ANDA
2017 – 2019
_
- R&D Facility in CA for development of General Injectables & 505(b)(2) products
2020 – 2021
_
- Portfolio of 25+ Injectables and 505(B)(2) under various stages of development
- 32+ ANDAs in Market
2022 – 2023
_
- Initiation of sterile Injectables focused manufacturing facility in CA with capabilities to manufacture various dosage forms
- Injectables ANDAs ready to launch in 2023
- Acquisition of new 503B manufacturing facility in los angeles, CA
- Commisiioned new solid oral (OSD) facility at Pittsburg, CA
2024-2025
_
- Completion of sterile injectable facility
- 13 Granted pattern for Pharma preparations
- Major joint venture agreement with AI formulation company for long acting injectable including GLP1
Let’s Connect – Fill Out the Inquiry Form